Beijing Qi-Huang Technology

Circode (officially Beijing Qi-Huang Technology) is a clinical-stage biotechnology company at the forefront of circular RNA (circRNA) research and development. Founded in 2021 by Professor Wei Wensheng of Peking University, the company leverages a proprietary platform to design and manufacture circRNA, which offers superior stability and prolonged protein expression compared to traditional linear mRNA. This technology aims to address the limitations of current RNA therapies, such as rapid degradation and the need for frequent administration. Circode's lead program is a circular RNA-based vaccine for COVID-19, which has entered clinical trials, and its pipeline includes additional programs in oncology and rare genetic disorders. The company is backed by a consortium of leading investors, including IDG Capital and Sequoia China, and is a key player in the global circular RNA landscape.